Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Recordati
Pharma
Sanofi sells rare disease med Enjaymo to Recordati for $825M
Recordati is paying $825 million upfront—plus $250 million in potential milestones—to pick up the global rights to Sanofi’s rare disease med Enjaymo.
Fraiser Kansteiner
Oct 4, 2024 10:11am
Recordati to acquire EUSA Pharma for €750m ($845 million)
Dec 3, 2021 11:10am
Recordati scores FDA nod for Cushing's disease med Isturisa
Mar 9, 2020 11:58am
Novartis offloads endocrine drugs to Recordati for $390M
Jul 15, 2019 12:25pm
CVC revs up rare disease ambitions with $3.5B Recordati buy
Jul 2, 2018 11:05am
CVC weighs $3B-plus Recordati buy: FT
Jun 20, 2018 12:29pm
